1.045
price up icon3.47%   0.035
after-market After Hours: 1.05 0.005 +0.48%
loading
Xortx Therapeutics Inc stock is traded at $1.045, with a volume of 8,017. It is up +3.47% in the last 24 hours and up +15.65% over the past month. XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
See More
Previous Close:
$1.01
Open:
$0.9781
24h Volume:
8,017
Relative Volume:
0.15
Market Cap:
$4.02M
Revenue:
-
Net Income/Loss:
$-736.70K
P/E Ratio:
-104.50
EPS:
-0.01
Net Cash Flow:
$-4.14M
1W Performance:
-1.42%
1M Performance:
+15.65%
6M Performance:
-25.36%
1Y Performance:
-60.96%
1-Day Range:
Value
$0.9781
$1.1216
1-Week Range:
Value
$0.9781
$1.1216
52-Week Range:
Value
$0.802
$3.13

Xortx Therapeutics Inc Stock (XRTX) Company Profile

Name
Name
Xortx Therapeutics Inc
Name
Phone
-
Name
Address
-
Name
Employee
3
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
XRTX's Discussions on Twitter

Compare XRTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
XRTX
Xortx Therapeutics Inc
1.045 4.02M 0 -736.70K -4.14M -0.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.19 127.64B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
603.58 65.95B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
656.65 37.92B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
273.55 32.98B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
254.16 26.92B 3.81B -644.79M -669.77M -6.24

Xortx Therapeutics Inc Stock (XRTX) Latest News

pulisher
May 01, 2025

XORTX Therapeutics Delays Yearly Report Filing - TipRanks

May 01, 2025
pulisher
Apr 30, 2025

XORTX Therapeutics Higher in U.S. Pre-market Trading, Says FDA Type B Meeting Positive - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Advances NDA Filing for Gout Treatment Following FDA Guidance - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Therapeutics Provides Update On FDA Type B Meeting Request - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Therapeutics Brief: Providing Update on FDA Type B Meeting Request - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Provides Update on FDA Type B Meeting Request - GlobeNewswire

Apr 30, 2025
pulisher
Apr 30, 2025

XORTX Therapeutics Inc. Provides Update on FDA Type B Meeting Request - marketscreener.com

Apr 30, 2025
pulisher
Apr 28, 2025

XORTX Therapeutics Inc. Announces Grant of European Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

XORTX Secures European Patent for Gout and Kidney Disease Therapies - TipRanks

Apr 28, 2025
pulisher
Apr 28, 2025

XORTX Announces Grant of European Patent - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

XORTX Secures Game-Changing European Patent for Gout and Kidney Disease Treatments - Stock Titan

Apr 28, 2025
pulisher
Apr 18, 2025

XORTX Therapeutics receives Nasdaq notice for non-compliance - MSN

Apr 18, 2025
pulisher
Apr 18, 2025

XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge - GuruFocus

Apr 18, 2025
pulisher
Apr 18, 2025

XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency - MSN

Apr 18, 2025
pulisher
Apr 17, 2025

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - GlobeNewswire

Apr 17, 2025
pulisher
Apr 17, 2025

XORTX Faces Nasdaq Price Compliance Challenge: 180 Days to Avoid Delisting Risk - Stock Titan

Apr 17, 2025
pulisher
Apr 11, 2025

XORTX Therapeutics: Stocks Undervalued by Analyst Consensus on TSX-V (XRTX) - The Globe and Mail

Apr 11, 2025
pulisher
Apr 09, 2025

1 Defense Stock to Buy for Protection During These Uncertain Times - The Globe and Mail

Apr 09, 2025
pulisher
Apr 01, 2025

XORTX Therapeutics Releases Annual Information Form for 2024 - TipRanks

Apr 01, 2025
pulisher
Mar 26, 2025

XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses - TipRanks

Mar 26, 2025
pulisher
Mar 19, 2025

XORTX Announces Update for Discussion with the FDA - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Therapeutics Announces Type B Meeting With FDA -March 19, 2025 at 07:56 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Advances Gout Treatment Program with FDA Discussions - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Therapeutics Brief: Announced Update for Discussion with the FDA -March 19, 2025 at 07:14 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Announces Update For Discussion With The FDA -March 19, 2025 at 07:05 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

XORTX Advances Revolutionary Gout Treatment Toward FDA Review - StockTitan

Mar 19, 2025
pulisher
Feb 24, 2025

Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease - DocWire News

Feb 24, 2025
pulisher
Feb 24, 2025

XORTX Starts Gout Program New Drug Application Talks With FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

XORTX Advances Gout Treatment Program with FDA Meeting Request - TipRanks

Feb 24, 2025
pulisher
Feb 24, 2025

XORTX Commences Gout Program NDA Discussions with the FDA - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

Can This New Gout Treatment Reach FDA Approval? XORTX Reveals Critical Timeline - StockTitan

Feb 24, 2025
pulisher
Feb 15, 2025

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - br.ADVFN.com

Feb 15, 2025
pulisher
Jan 29, 2025

XORTX to Present at Microcap Conference - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

XORTX Therapeutics Engages Investors at Microcap Conference - TipRanks

Jan 29, 2025
pulisher
Jan 29, 2025

Revolutionary Gout Treatment Developer XORTX Reveals Game-Changing Pipeline Updates - StockTitan

Jan 29, 2025
pulisher
Jan 29, 2025

XRTXXortx Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Jan 29, 2025
pulisher
Jan 24, 2025

XORTX Therapeutics Announces Auditor Transition - MSN

Jan 24, 2025
pulisher
Jan 22, 2025

XORTX Announces Change of Auditor - TipRanks

Jan 22, 2025
pulisher
Jan 21, 2025

XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks

Jan 21, 2025
pulisher
Jan 17, 2025

XORTX Therapeutics Announces Auditor Change to Davidson & Company LLP - StockTitan

Jan 17, 2025
pulisher
Jan 16, 2025

XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel

Jan 16, 2025
pulisher
Jan 15, 2025

Now Is The Time To Build A Position In XORTX Therapeutics Inc (NASDAQ:XRTX) - Marketing Sentinel

Jan 15, 2025
pulisher
Jan 06, 2025

XORTX Therapeutics Expands Pipeline with Late-Stage Gout Program - TipRanks

Jan 06, 2025
pulisher
Jan 06, 2025

XORTX Adds Late Stage Gout Program to Pipeline - GlobeNewswire

Jan 06, 2025
pulisher
Jan 06, 2025

XORTX Launches XRx-026 Program for Allopurinol-Intolerant Gout Patients, Targets FDA Approval - StockTitan

Jan 06, 2025

Xortx Therapeutics Inc Stock (XRTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$72.58
price up icon 0.39%
$21.55
price up icon 0.33%
$33.00
price up icon 0.33%
$28.02
price up icon 0.43%
$101.10
price down icon 3.66%
biotechnology ONC
$254.16
price down icon 0.63%
Cap:     |  Volume (24h):